MX2023005563A - Profilaxis y tratamiento del angioedema. - Google Patents
Profilaxis y tratamiento del angioedema.Info
- Publication number
- MX2023005563A MX2023005563A MX2023005563A MX2023005563A MX2023005563A MX 2023005563 A MX2023005563 A MX 2023005563A MX 2023005563 A MX2023005563 A MX 2023005563A MX 2023005563 A MX2023005563 A MX 2023005563A MX 2023005563 A MX2023005563 A MX 2023005563A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- angioedema
- human patient
- alleviate
- symptoms
- Prior art date
Links
- 208000028185 Angioedema Diseases 0.000 title abstract 8
- 238000011321 prophylaxis Methods 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 3
- 101800004538 Bradykinin Proteins 0.000 abstract 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 abstract 2
- 102100035792 Kininogen-1 Human genes 0.000 abstract 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 230000001154 acute effect Effects 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere a un antagonista del receptor B2 de bradicinina (BK) que tiene la fórmula estructural (I) para su uso en el tratamiento profiláctico del angioedema (AE) o en un método para tratar el AE, en donde dicho compuesto se administra al menos una vez por vía oral en una dosis terapéuticamente eficaz para prevenir, aliviar o tratar los síntomas del AE. La presente invención también proporciona un método de tratamiento profiláctico de un paciente humano que padece AE o un método para el tratamiento a demanda de un paciente humano que ha experimentado un ataque agudo de AE, que comprende administrar por vía oral al paciente humano una dosis terapéuticamente eficaz del compuesto de fórmula (I) al menos una vez para aliviar o tratar de este modo los síntomas de AE del paciente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20207273 | 2020-11-12 | ||
| PCT/EP2021/081493 WO2022101395A1 (en) | 2020-11-12 | 2021-11-12 | Prophylaxis and treatment of angioedema |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005563A true MX2023005563A (es) | 2023-09-11 |
Family
ID=73401436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005563A MX2023005563A (es) | 2020-11-12 | 2021-11-12 | Profilaxis y tratamiento del angioedema. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230338358A1 (es) |
| EP (1) | EP4243824A1 (es) |
| JP (1) | JP2023549849A (es) |
| KR (1) | KR20230107269A (es) |
| CN (1) | CN116685353A (es) |
| AU (1) | AU2021376885A1 (es) |
| CA (1) | CA3198246A1 (es) |
| IL (1) | IL302887A (es) |
| MX (1) | MX2023005563A (es) |
| WO (1) | WO2022101395A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202345810A (zh) * | 2022-03-25 | 2023-12-01 | 瑞士商帕法瑞斯有限責任公司 | 包含緩激肽ｂ２受體拮抗劑之固態延長釋放組成物 |
| WO2023180575A1 (en) * | 2022-03-25 | 2023-09-28 | Pharvaris Gmbh | Solid composition comprising solubilised bradykinin b2-receptor antagonists |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA50804B1 (fr) | 2017-11-24 | 2022-05-31 | Pharvaris Netherlands B V | Nouveaux antagonistes des récepteurs de bradykinine b2 |
-
2021
- 2021-11-12 CN CN202180080857.7A patent/CN116685353A/zh active Pending
- 2021-11-12 WO PCT/EP2021/081493 patent/WO2022101395A1/en active Application Filing
- 2021-11-12 AU AU2021376885A patent/AU2021376885A1/en active Pending
- 2021-11-12 MX MX2023005563A patent/MX2023005563A/es unknown
- 2021-11-12 CA CA3198246A patent/CA3198246A1/en active Pending
- 2021-11-12 KR KR1020237018410A patent/KR20230107269A/ko unknown
- 2021-11-12 IL IL302887A patent/IL302887A/en unknown
- 2021-11-12 US US18/036,719 patent/US20230338358A1/en active Pending
- 2021-11-12 EP EP21805547.3A patent/EP4243824A1/en active Pending
- 2021-11-12 JP JP2023528620A patent/JP2023549849A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL302887A (en) | 2023-07-01 |
| AU2021376885A1 (en) | 2023-06-08 |
| US20230338358A1 (en) | 2023-10-26 |
| CA3198246A1 (en) | 2022-05-19 |
| KR20230107269A (ko) | 2023-07-14 |
| EP4243824A1 (en) | 2023-09-20 |
| JP2023549849A (ja) | 2023-11-29 |
| WO2022101395A1 (en) | 2022-05-19 |
| CN116685353A (zh) | 2023-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023005563A (es) | Profilaxis y tratamiento del angioedema. | |
| NZ572049A (en) | Method for treatment of constipation-predominant irritable bowel syndrome | |
| ZA202109010B (en) | Compounds and methods for the treatment of covid-19 | |
| MX2018001435A (es) | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. | |
| NZ745065A (en) | Methods for treatment and prophylaxis of hiv and aids | |
| MX2021002349A (es) | Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario. | |
| WO2022188898A3 (zh) | 化合物盐酸赛庚啶在制备预防或治疗非洲猪瘟药物中的应用 | |
| WO2022197720A3 (en) | Compositions and methods for treating coronavirus infection | |
| MX2022012135A (es) | Métodos para tratar la enfermedad de coronavirus de 2019. | |
| MX2022007911A (es) | Procedimiento de tratamiento de una infeccion virica usando un agonista de tlr7. | |
| MX2023013403A (es) | Composicion farmaceutica para prevenir o tratar la fibrosis. | |
| MX2022011490A (es) | Tratamiento o metodo de prevencion de falla cardiaca cronica. | |
| MX2023007420A (es) | Tratamiento de glomerulopatia c3 usando un inhibidor de c5a. | |
| WO2016090107A3 (en) | Treatment of hepatitis delta virus infection | |
| MX2022011519A (es) | Metodos de uso de inhibidores de la quinasa rho para tratar demencia frontotemporal. | |
| MX2022003845A (es) | Tratamientos cognitivos medicinales. | |
| MX2021001228A (es) | Composicion para uso en la prevencion y/o tratamiento de la mucosa genitourinaria. | |
| MX2008016520A (es) | Medicamentos. | |
| MX2021006209A (es) | Montelukast para el tratamiento de la osteoartritis erosiva de la mano. | |
| MX2021001549A (es) | Una composicion farmaceutica para el tratamiento seguro y efectivo del dolor de rodilla y/o cadera. | |
| MX2022015760A (es) | Inhibidor del receptor tipo toll 7 (tlr7) en combinacion con prednisolona o hidroxicloroquina para el tratamiento del lupus eritematoso cutaneo. | |
| MX2020007404A (es) | Metodos y terapia de combincion para tratar cancer. | |
| MX2023001358A (es) | N´-(2-cloro-6-metilbenzoil)-4-metil-3-[2-(3-quinolil) etinil]-benzohidrazida para el tratamiento de la enfermedad de alzheimer. | |
| MX2022015146A (es) | Tratamiento de la artritis reumatoide. | |
| MX2022002684A (es) | Metodo de tratamiento o prevencion de la enfermedad renal cronica. |